76091-01-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-METHOXY-PHENYL)-1H-PYRAZOL-3-YLAMINE is used as a pharmaceutical compound for its potential therapeutic applications. 1-(4-METHOXY-PHENYL)-1H-PYRAZOL-3-YLAMINE's anti-inflammatory, analgesic, and antioxidant properties make it a candidate for the development of new drug candidates to treat various diseases and conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(4-METHOXY-PHENYL)-1H-PYRAZOL-3-YLAMINE is used as a subject of study for its potential to contribute to the development of novel drugs. Its unique chemical structure and properties are of interest to researchers seeking to understand and exploit its pharmacological potential.
Used in Drug Development:
1-(4-METHOXY-PHENYL)-1H-PYRAZOL-3-YLAMINE is utilized as a starting point in the development of new drugs. Its properties, such as anti-inflammatory, analgesic, and antioxidant effects, make it a valuable compound for creating medications that could address a range of health issues.

InChI:InChI=1/C10H11N3O/c1-14-9-4-2-8(3-5-9)13-7-6-10(11)12-13/h2-7H,1H3,(H2,11,12)

Upstream product

• 60838-50-8 3-methoxy-2-propenenitrile 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 
• 1820-80-0 3-aminopyrazole 
• 696-62-8 para-iodoanisole 

Downstream Products

• 1215007-09-2 C₁₀H₁₀BrN₃O 

Relevant academic research and scientific papers

Copper(I)/Copper(II)-Assisted Tandem Catalysis: The Case Study of Ullmann/Chan-Evans-Lam N1,N3-Diarylation of 3-Aminopyrazole

Unprecedented CuI/CuII-assisted tandem catalysis allowing an Ullmann/Chan-Evans-Lam sequence was achieved. This three-component, one-pot reaction triggered by a change in the oxidation state of the metal leads to the selective N1,N3-diarylation of 3-aminopyrazole. This new method should be a valuable tool for small-molecule drug discovery that requires suitable regio- and/or chemoselective strategies for the N-arylation of nitrogen-containing heterocycles. Tandem power: The first assisted tandem copper-catalyzed process, triggered by a change in the oxidation state of the metal, is developed to allow a one-pot Ullman/Chan-Evans-Lam sequence leading to the selective N1,N3-diarylation of 3-aminopyrazole.

Regiocontrolled synthesis of 3- and 5-aminopyrazoles, pyrazolo[3,4-d] pyrimidines, pyrazolo[3,4-b]pyridines and pyrazolo[3,4-b]quinolinones as MAPK inhibitors

Microwave irradiation of a hydrazine and 3-methoxyacrylonitrile, ethoxymethylenemalononitrile or ethyl acetoacetate provides rapid access to 3- or 5-substituted pyrazoles in excellent yield and with total regiocontrol in a process that can be switched from one regioisomer to the other by choice of conditions. Subsequent reaction, either by microwave-assisted hydrolysis and cyclocondensation with formamide, Hantzsch-type three-component reaction with an aldehyde and ketone, or by cyclocondensation with 2-nitrobenzaldehyde, provides the pyrazolo[3,4-d]pyrimidine, pyrazolo[3,4-b]pyridine or pyrazolo[3,4-b] quinolin-4-one framework, respectively, of inhibitors of mitogen-activated protein kinases.

Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy

New, selective 3-aminopyrazole based MK2-inhibitors were discovered by scaffold hopping strategy. The new derivatives proved to inhibit intracellular phosphorylation of hsp27 as well as LPS-induced TNFα release in cells. In addition, selected derivative 1